全文获取类型
收费全文 | 5202篇 |
免费 | 453篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 33篇 |
儿科学 | 102篇 |
妇产科学 | 141篇 |
基础医学 | 940篇 |
口腔科学 | 104篇 |
临床医学 | 523篇 |
内科学 | 961篇 |
皮肤病学 | 184篇 |
神经病学 | 783篇 |
特种医学 | 196篇 |
外科学 | 487篇 |
综合类 | 44篇 |
一般理论 | 4篇 |
预防医学 | 348篇 |
眼科学 | 138篇 |
药学 | 273篇 |
中国医学 | 8篇 |
肿瘤学 | 395篇 |
出版年
2024年 | 21篇 |
2023年 | 104篇 |
2022年 | 161篇 |
2021年 | 240篇 |
2020年 | 169篇 |
2019年 | 218篇 |
2018年 | 245篇 |
2017年 | 193篇 |
2016年 | 251篇 |
2015年 | 252篇 |
2014年 | 280篇 |
2013年 | 319篇 |
2012年 | 505篇 |
2011年 | 480篇 |
2010年 | 239篇 |
2009年 | 219篇 |
2008年 | 311篇 |
2007年 | 257篇 |
2006年 | 260篇 |
2005年 | 239篇 |
2004年 | 168篇 |
2003年 | 181篇 |
2002年 | 135篇 |
2001年 | 15篇 |
2000年 | 11篇 |
1999年 | 14篇 |
1998年 | 26篇 |
1997年 | 23篇 |
1996年 | 17篇 |
1995年 | 11篇 |
1994年 | 14篇 |
1993年 | 5篇 |
1992年 | 6篇 |
1991年 | 5篇 |
1990年 | 4篇 |
1988年 | 3篇 |
1986年 | 6篇 |
1985年 | 3篇 |
1983年 | 4篇 |
1981年 | 4篇 |
1980年 | 2篇 |
1979年 | 3篇 |
1976年 | 2篇 |
1972年 | 2篇 |
1964年 | 2篇 |
1962年 | 2篇 |
1961年 | 2篇 |
1933年 | 4篇 |
1931年 | 2篇 |
1926年 | 5篇 |
排序方式: 共有5664条查询结果,搜索用时 15 毫秒
71.
72.
73.
74.
75.
76.
77.
78.
The effects of five-year growth hormone replacement therapy on muscle strength in elderly hypopituitary patients 总被引:3,自引:0,他引:3
Götherström G Bengtsson BA Sunnerhagen KS Johannsson G Svensson J 《Clinical endocrinology》2005,62(1):105-113
OBJECTIVE: Little is known of the long-term effects of GH replacement therapy on muscle strength in elderly adults with adult onset GH deficiency (GHD). In this study, the effects of 5 years of GH replacement therapy on muscle function were determined in adults over 60 years of age with adult onset GHD. DESIGN: A prospective, open-label, single-centre study. Patients Twenty-six (12 male and 14 female) consecutive hypopituitary adults with adult onset GHD, mean age 65.0 (range 61-74) years. MEASUREMENTS: Upper leg muscle strength was measured using a Kin-Com dynamometer. Right and left handgrip strength were measured using an electronic grip force instrument. RESULTS: The mean insulin-like growth factor-I (IGF-I) SD score increased from -1.10 at baseline to 1.21 at end of the study. Body weight was unchanged during the 5-year study. A sustained increase in lean body mass and a sustained reduction of body fat was observed as measured using dual-energy X-ray absorptiometry (DEXA). The GH replacement therapy induced a sustained increase in isometric (60 degrees ) knee flexor strength. After statistical correction for age and sex variables using observed/predicted value ratios, a sustained increase was also observed in concentric knee flexor strength at an angular velocity of 60 degrees /s, concentric knee extensor strength at 60 degrees /s and 180 degrees /s, and peak right handgrip strength. At baseline, knee flexor strength was 90-96% of predicted, knee extensor strength was 85-87% of predicted, and hand-grip strength was 74-80% of predicted values. At study end, knee flexor strength was 98-106% of predicted, knee extensor strength was 90-100% of predicted, and hand-grip strength was 80-87% of predicted values. CONCLUSION: Elderly patients with adult onset GH deficiency had decreased baseline muscle strength also after correction for age and sex. The 5-year GH replacement therapy normalized knee flexor strength and improved, but did not fully normalize, knee extensor strength and handgrip strength. 相似文献
79.
Macrophage inflammatory protein-1alpha (MIP-1alpha) is an interesting chemokine because in addition to its variety proinflammatory activities including chemotaxis and immunomodulation, it is a potent inhibitor of hematopoetic stem cell proliferation. Inhibition of erythroid progenitor cells due to MIP-1alpha or other cytokines can play a role in the pathogenesis of anemia which is one of the most common extra-articular features of active rheumatoid arthritis (RA). In 84 patients with RA, serological and immunological parameters were assessed to detect inflammatory mechanisms and anemia in relation to the serum concentrations of MIP-1alpha. All patients fulfilled the ACR criteria for the diagnosis of a definite or classic RA. We used a quantitative enzyme immuno assay for the detection of MIP-1alpha as well as for the measurement of the acute phase protein serum amyloid A (SAA), the erythropoiesis inducer erythropoietin (EPO) and the transferrin receptor (TfR). The immune activation marker neopterin was measured radioimmunologically. Half of the patients with RA were anemic with hemoglobin values below 12 g/dl. MIP-1alpha was found to be elevated significantly in serum of patients with active rheumatoid arthritis and in patients with anemia. Most of the anemic patients with markedly elevated acute phase reactions had an anemia with chronic diseases and not a functional iron deficiency alone. TfR correlated with EPO. The results show that enhanced expression of MIP-1alpha is indicative of systemic inflammation in RA. Moreover, besides the regulation of inflammatory processes, this chemokine may influence the pathogenesis of anemia in RA patients. 相似文献
80.
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses 总被引:2,自引:0,他引:2
Hipp MM Hilf N Walter S Werth D Brauer KM Radsak MP Weinschenk T Singh-Jasuja H Brossart P 《Blood》2008,111(12):5610-5620
The tyrosine kinase inhibitors sorafenib and sunitinib are approved for the treatment of patients with malignant diseases. To analyze the possible use of these compounds in combination with immunotherapeutic approaches, we analyzed the effects of both inhibitors on the immunostimulatory capacity of human dendritic cells (DCs) and the induction of primary immune responses in vivo. Sorafenib, but not sunitinib, inhibits function of DCs, characterized by reduced secretion of cytokines and expression of CD1a, major histocompatibility complex, and costimulatory molecules in response to TLR ligands as well as by their impaired ability to migrate and stimulate T-cell responses. These inhibitory effects are mediated by inhibition of PI3 and MAP kinases and NFB signaling. In contrast, sorafenib had no influence on the phenotype and proliferation of T cells. To analyze the effects of both TKIs on cytotoxic T-cell induction in vivo, C57BL/6 mice were pretreated with sorafenib or sunitinib and immunized with OVA257-264 peptide. Sorafenib, but not sunitinib, application significantly reduced the induction of antigen-specific T cells. Numbers of regulatory T cells were reduced in peripheral blood mononuclear cells from mice treated with sunitinib. These results indicate that sunitinib, but not sorafenib, is suitable for combination with immunotherapeutic approaches for treatment of cancer patients. 相似文献